Myelofibrosis
ASH Seeks Public Comment on Draft Recommendations for New Guidelines on Myelofibrosis
ASH is now accepting public comments on draft recommendations on myelofibrosis. Comments will be accepted until November 24, 2025. We encourage all interested healthcare professionals, stakeholder organizations, and individuals to share their feedback on these draft recommendations. All comments will be reviewed by the guideline panel before the guidelines are finalized.
Myelofibrosis Draft Recommendations
Please submit all comments to [email protected].
ASH has initiated an effort to develop evidence-based clinical practice guidelines for myelofibrosis that meet the highest standards of development, rigor and trustworthiness. Development of these guidelines, including systematic evidence review, will be supported by a methodology team. With their partnership, ASH will work to convene an initial panel of experts to determine the scope of the guideline, review evidence and formulate recommendations.
Download ASH’s COI policy to learn more about management of conflicts of interest in the development of Clinical Practice Guidelines by the American Society of Hematology.
ASH continues its long-standing commitment to supporting scientists and clinicians from a wide variety of backgrounds in medicine and embraces diverse voices across the patient and health care communities. Learn more about ASH’s commitment to excellence through expansion and inclusion in health care.